Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Skin Neoplasms 1Neoplasms, Squamous Cell 1Neoplasms, Basal Cell 1Melanoma 1Carcinoma, Squamous Cell 1Carcinoma, Basal Cell 1

Interventions

Cyclophosphamide 909Carboplatin 787pembrolizumab 744Paclitaxel 742Cisplatin 709Bevacizumab 706Gemcitabine 619Docetaxel 579Rituximab 548Radiotherapy 541Dexamethasone 511Nivolumab 488Doxorubicin 444Fluorouracil 392Capecitabine 376Etoposide 358Pemetrexed 337Cytarabine 335Oxaliplatin 333Lenalidomide 328Prednisone 326fludarabine phosphate 316Erlotinib Hydrochloride 314Trastuzumab 300Leucovorin 299fludarabine 296Vincristine 287Filgrastim 284Bortezomib 284Cetuximab 276

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Has results × Risk Factors × Clear all
NCT03509467 2025-12-19

Using MC1R Genotype to Impact Melanoma Risk Behavior

H. Lee Moffitt Cancer Center and Research Institute

Phase NA Completed
2,054 enrolled 92 charts
Dermatologic

Carcinoma, Basal Cell, Carcinoma, Squamous Cell, Melanoma, Skin Neoplasms, Neoplasms, Basal Cell, Neoplasms, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡